Steel Grove Capital Advisors LLC Purchases 917 Shares of Eli Lilly and Company $LLY

Steel Grove Capital Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 150.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,526 shares of the company’s stock after acquiring an additional 917 shares during the period. Steel Grove Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $1,765,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of America Corp DE acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $13,522,666,000. Jupiter Topco LLC acquired a new position in shares of Eli Lilly and Company during the second quarter valued at about $4,667,180,000. Fifth Third Bancorp grew its holdings in shares of Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Eli Lilly and Company by 353.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock worth $1,425,859,000 after acquiring an additional 1,208,510 shares in the last quarter. Finally, Corient Private Wealth LP bought a new stake in shares of Eli Lilly and Company during the second quarter worth about $764,116,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded down $13.92 during midday trading on Tuesday, reaching $1,168.70. The company had a trading volume of 658,782 shares, compared to its average volume of 2,945,984. The company’s 50 day moving average price is $1,175.57 and its 200 day moving average price is $1,100.31. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market cap of $1.10 trillion, a P/E ratio of 39.25, a P/E/G ratio of 1.47 and a beta of 0.46. Eli Lilly and Company has a 52-week low of $783.85 and a 52-week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the company posted $6.31 earnings per share. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 36.19 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 in the last quarter. Insiders own 0.14% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts remain optimistic about Lilly’s earnings and growth prospects. Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 forecast to $47.30, while RBC reiterated an “outperform” rating with a $1,500 price target. RBC reiterates outperform rating
• Positive Sentiment: Strong demand for Zepbound and other cardiometabolic medicines is supporting expectations that Lilly could raise its full-year revenue outlook. Analysts and investors also see substantial long-term potential in retatrutide, which could become a larger growth driver than Zepbound if clinical results and commercialization proceed successfully. Lilly revenue outlook
• Positive Sentiment: Phase 3b data for a Taltz-Zepbound combination showed improved skin clearance and weight loss in patients with plaque psoriasis and obesity, potentially expanding Lilly’s ability to target overlapping inflammatory and metabolic conditions. Taltz and Zepbound Phase 3b data
• Positive Sentiment: Lilly is collaborating with Prelude Therapeutics to evaluate a cancer drug combination involving PRT13722, Verzenio and Inluriyo, adding another potential pipeline opportunity. Prelude collaboration with Lilly
• Neutral Sentiment: Lilly’s revenue growth substantially exceeds that of major pharmaceutical peers, but its premium earnings multiple leaves less room for execution mistakes. Investor confidence therefore depends heavily on the company’s pipeline and future obesity-drug launches. Lilly valuation and growth outlook
• Negative Sentiment: A combination treatment produced more weight loss than Zepbound alone but also had materially higher discontinuation rates, raising questions about tolerability, adherence and the commercial potential of future obesity therapies. Lilly weight-loss combination study
• Negative Sentiment: Retatrutide is already facing illicit online sales before approval, highlighting potential regulatory, safety and brand risks for Lilly’s highly anticipated obesity pipeline. Retatrutide black-market sales

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a report on Thursday, September 17th. Citigroup lifted their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Bank of America boosted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Sanford C. Bernstein increased their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. Finally, Leerink Partners raised their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,313.43.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.